Correlation of safety and efficacy of atezolizumab therapy across indications
This analysis demonstrates a correlation between irAEs and improved OS with atezolizumab by severity grade and the most common irAEs by organ involvement. Low-grade irAEs are significantly associated with improved OS, while specific high-grade irAEs are associated with poorer OS, underscoring the importance of early recognition and management of toxicity to optimize benefit/risk balance.
Authors
- Rajat Mohindra (ORCID: https://orcid.org/0009-0000-4233-5210)
- Vidya Maiya
- Gonzalo Durán-Pacheco
- Jarushka Naidoo (ORCID: https://orcid.org/0000-0002-3470-8686)
- Guru Sonpavde (ORCID: https://orcid.org/0000-0002-1010-9611)
- Corey Carter (ORCID: https://orcid.org/0000-0002-3012-4819)
- Laurent Essioux
- Javier Puente (ORCID: https://orcid.org/0000-0002-6910-1331)
- Mark A. Socinski (ORCID: https://orcid.org/0000-0003-2915-9325)
- G. Scott Chandler (ORCID: https://orcid.org/0000-0001-5339-9906)
- Jose Vicente Cardona
Institutions
- Roche (Switzerland) (CH)
- Royal College of Surgeons in Ireland (IE)
- Johns Hopkins University (US)
- Institut Pasteur (FR)
- Johns Hopkins Medicine (US)
- AdventHealth East Orlando (US)
- Beaumont Hospital (IE)
- Florida Hospital Cancer Institute (US)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1136/jitc-2024-010158
- Citations
- 6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.70
Funders
- F. Hoffmann-La Roche
- Genentech